

SUMMARY OF PRODUCT CHARACTERISTICS (SPC):

1. NAME OF THE MEDICINAL PRODUCT

CORZOLE 400 (Albendazole Chewable Tablets 400 mg)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each chewable tablet contains 400 mg albendazole
For the full list of excipients, see section 6.1

3. DOSAGE FORM AND STRENGTH

Chewable Tablets

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

CORZOLE 400 is a benzimidazole carbamate with anthelmintic and antiprotozoal activity against intestinal and tissue parasites.

Intestinal Infections and Cutaneous Larva Migrans

CORZOLE 400 has activity against the following intestinal and tissue parasites: Round-worm (*Ascaris lumbricoides*), pin-worm (*Enterobius vermicularis*), hook-worm (*Necator americanus*, *Ancylostoma duodenale*), whip-worm (*Trichuris trichiura*), thread-worm (*Strongyloides stercoralis*), tape-worm (*Taenia spp* and *Hymenolepis nana* only in the case of associated parasitism), Chlonorchiasis (*Chlonorchis sinensis*), Opisthorchiasis (*Opisthorchis viverrini*) and cutaneous larva migrans; Giardiasis (*G.lamblia*, *G.duodenalis*, *G.intestinalis*, *Lambliia intestinalis*) in children.

Systemic Helminth Infections

CORZOLE 400 is indicated for the treatment of the following systemic helminth infections (see 5.2 *Pharmacodynamic Properties* for details of sensitive helminth species).

- *Echinococcosis*

CORZOLE 400 shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. Experience with bone cysts and those in the heart and central nervous system is limited.

Cystic Echinococcosis (caused by *Echinococcus granulosus*)

CORZOLE 400 is used in patients with cystic echinococcosis:

1. where surgical intervention is not feasible.
2. prior to surgical intervention.

3. post-operatively if pre-operative treatment was too short, if spillage has occurred or if viable material was found at surgery.
4. following percutaneous drainage of cysts for diagnostic or therapeutic reasons.

Alveolar Echinococcosis (caused by *Echinococcus multilocularis*)

CORZOLE 400 is used in patients with alveolar echinococcosis:

1. in inoperable disease, particularly in cases of local or distant metastasis.
2. following palliative surgery.
3. following radical surgery or liver transplantation.

- **Neurocysticercosis** (larval *Taenia solium* infection)

CORZOLE 400 is used for the treatment of patients with:

1. single or multiple cystic or granulomatous lesions of the brain parenchyma.
2. arachnoidal or intraventricular cysts.
3. racemose cysts.

4.2 Posology and Method of Administration

Intestinal Infections and Cutaneous Larva Migrans

No special procedures, such as fasting or purging, are required.

If the patient is not cured after three weeks, a second course of treatment is indicated.

The tablets can be chewed or taken with water. Some people, particularly young children, may experience difficulties swallowing the tablets whole and should be encouraged to chew the tablets with a little water; alternatively the tablets may be crushed.

Indications	Age	Dose	Period
- Round-worm - Pin-worm* - Hook-worms - Whip-worm	Adults and children over 2 years of age.	one 400 mg tablet	Single dose.
- Strongyloidiasis - Taeniasis - Hymenolepiasis=	Adults and children over 2 years of age.	one 400 mg tablet	One dose per day for 3 days.
- Chlonorchiasis - Opisthorchiasis	Adults and children over 2 years of age.	one 400 mg tablet	Two doses per day for 3 days.
- Giardiasis	Children 2 - 12 years of age only.	one 400 mg tablet	One dose per day for 5 days.
- Cutaneous Larva Migrans	Adults and children over 2 years of age.	one 400 mg tablet	One dose per day for 1 to 3 days.

*In order to obtain a complete cure in the case of pin-worm infestation, prescribe strict measures of hygiene, also treat the relatives and individuals sharing the same housing.

=In cases of proven Hymenolepiasis, retreatment in 10 to 21 days is recommended.

- **Elderly**

Experience in patients 65 years of age or older is limited. Reports indicate that no dosage

adjustment is required, however, *CORZOLE 400* should be used with caution in elderly patients with evidence of hepatic dysfunction (see *Hepatic Impairment* below and 5.3 *Pharmacokinetic Properties*).

- ***Renal impairment***

Since renal elimination of albendazole and its primary metabolite, albendazole sulfoxide, is negligible, it is unlikely that clearance of these compounds would be altered in these patients. No dosage adjustment is required, however, patients with evidence of renal impairment should be carefully monitored.

- ***Hepatic impairment***

Since albendazole is rapidly metabolised by the liver to the primary pharmacologically active metabolite, albendazole sulfoxide, hepatic impairment would be expected to have significant effects on the pharmacokinetics of albendazole sulfoxide. Patients with abnormal liver function test results (transaminases) prior to commencing albendazole therapy should be carefully monitored.

Systemic helminth infections

CORZOLE 400 should be taken with meals (see 5.3 *Pharmacokinetic Properties*).

There has been limited experience to date with the use of *CORZOLE 400* at high doses in children under 6 years of age; therefore use in children less than 6 years is not recommended.

The tablets can be chewed or taken with water. Some people, particularly young children, may experience difficulties swallowing the tablets whole and should be encouraged to chew the tablets with a little water; alternatively the tablets may be crushed.

Dosages are dependent on the parasite involved, the weight of the patient, and the severity of the infection:

Infection	Patient Body Weight	Dose	Duration of Dosage
<i>Cystic Echinococcosis</i>	> 60 kg	800 mg given in two divided doses of 400 mg.	Daily for 28 days. Treatment for 28 days may be repeated after a 14 day period without treatment for a total of three cycles.
	< 60 kg	15 mg/kg, given in two equally divided doses (maximum dose 800 mg/day).	
<i>- Inoperable and multiple cysts</i>			Up to three 28 day cycles of <i>CORZOLE 400</i> treatment may be given for the treatment of liver, lung and peritoneal cysts. More prolonged treatment may be required for sites such as bone and brain.

- <i>Pre-operative</i>			Two 28 day cycles should be given where possible prior to surgery. Where surgical intervention is necessary before completion of two cycles, <i>CORZOLE 400</i> should be given for as long as possible.
- <i>Post-operative</i> - <i>After percutaneous cyst drainage</i>			Where only a short pre-operative course has been given (less than 14 days) and in cases where emergency surgery is required, <i>CORZOLE 400</i> should be given post-operatively for two 28 day cycles separated by 14 drug free days. Additionally, where cysts are found to be viable following pre-surgical treatment or where spillage has occurred, a full-two cycle course should be given.
<i>Alveolar Echinococcosis</i>	> 60 kg	800 mg, given in two equally divided doses.	Daily for 28 days. Treatment for 28 days may be repeated after a 14 day period without treatment.
	< 60 kg	15 mg/kg given in two equally divided doses (maximum dose 800 mg/day).	Treatment may need to be prolonged for months or years. Continuous treatment at the same dose has been used for periods of up to 20 months.†
<i>Neurocysticercosis</i> ±	> 60 kg	800 mg, given in two equal divided doses.	Daily for 7 to 30 days, dependent on the response. A second course
Infection	Patient Body Weight	Dose	Duration of Dosage
	< 60 kg	15 mg/kg, given in two equal divided doses (maximum dose 800 mg/day).	may be given with a two-week interval between dose regimes.
- <i>Parenchymal cysts and granulomas</i>	> 60 kg	800 mg, given in two equal divided doses.	Treatment is usually continued for a minimum of 7 days up to 28 days.
	< 60 kg	15 mg/kg, given in two equal divided doses (maximum dose 800 mg/day).	
- <i>Arachnoidal and ventricular cysts</i>	> 60 kg	800 mg, given in two equal divided doses.	Treatment for 28 days is normally necessary in non-parenchymal

	< 60 kg	15 mg/kg, given in two equal divided doses (maximum dose 800 mg/day).	cysts.
- <i>Racemose cysts</i>	> 60 kg	800 mg, given in two equal divided doses.	Treatment is normally required for at least 28 days. This has been given as a continuous treatment, the duration being determined by clinical and radiological response.
	< 60 kg	15 mg/kg, given in two equal divided doses (maximum dose 800 mg/day).	

†Alveolar Echinococcosis: Treatment is normally given in 28 day cycles as for cystic echinococcosis. It may have to be continued for months or even years. Current follow up suggests that survival times are substantially improved following prolonged treatment. Continuous treatment has been shown in a limited number of patients to lead to apparent cure.

±Neurocysticercosis: Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids are recommended to prevent cerebral hypertensive episodes during the first week of treatment.

- ***Elderly***

Refer section 4.2 *Posology and Method of Administration - Intestinal Infections and Cutaneous Larva Migrans; Elderly for details.*

- ***Renal impairment***

Refer section 4.2 *Posology and Method of Administration*

- ***Hepatic impairment***

Since albendazole is rapidly metabolised by the liver to the primary pharmacologically active metabolite, albendazole sulfoxide, hepatic impairment would be expected to have significant effects on the pharmacokinetics of albendazole sulfoxide. Patients with abnormal liver function test results (transaminases) prior to commencing albendazole therapy should be carefully evaluated and therapy should be discontinued if liver enzymes are significantly increased or full blood count decreased by a clinically significant level (see 4.4 *Special Warnings and Precautions for Use* and 4.8 *Undesirable Effects*).

4.3 Contraindications

CORZOLE 400 should not be administered during pregnancy, or in women thought to be pregnant.

CORZOLE 400 is contra-indicated in patients with a known history of hypersensitivity to the drug (albendazole or constituents).

4.4 Special Warnings and Precautions for Use

Use in Intestinal Infections and Cutaneous Larva Migrans (shorter duration of treatment at lower doses)

In order to avoid administering *CORZOLE 400* during early pregnancy, women of childbearing age should initiate treatment during the first week of menstruation or after a negative pregnancy test.

Treatment with *CORZOLE 400* may uncover pre-existing neurocysticercosis, particularly in areas with high taenosis infection. Patients may experience neurological symptoms e.g. seizures, increased intracranial pressure and focal signs as a result of an inflammatory reaction caused by death of the parasite within the brain. Symptoms may occur soon after treatment, appropriate steroid and anticonvulsant therapy should be started immediately.

Use in Systemic Helminth Infections (longer duration of treatment at higher doses)

CORZOLE 400 treatment has been associated with mild to moderate elevations of hepatic enzymes. Hepatic enzymes generally normalise on discontinuation of treatment. Case reports of hepatitis have also been received (see 4.8 *Undesirable Effects*). Liver function tests should be obtained before the start of each treatment cycle and at least every two weeks during treatment. If hepatic enzymes are significantly increased (greater than twice the upper limit of normal), *CORZOLE 400* should be discontinued. *CORZOLE 400* treatment may be restarted when hepatic enzymes have returned to normal limits, but patients should be carefully monitored for a recurrence.

CORZOLE 400 has been shown to cause bone marrow suppression and therefore blood counts should be performed at the start and every two weeks during each 28 day cycle. Patients with liver disease, including hepatic echinococcosis, appear to be more susceptible to bone marrow suppression leading to pancytopenia, aplastic anaemia, agranulocytosis and leukopenia and therefore warrant closer monitoring of blood counts. *CORZOLE 400* should be discontinued if clinically significant decreases in blood cell counts occur (see 4.2 *Posology and Method of Administration* and 4.8 *Undesirable Effects*).

In order to avoid administering *CORZOLE 400* during early pregnancy, women of childbearing ages should:

- initiate treatment only after a negative pregnancy test. These tests should be repeated at least once before initiating the next cycle.
- be advised to take effective precautions against conception during and within one month of completion of treatment with *CORZOLE 400* for a systemic infection.

Symptoms associated with an inflammatory reaction following death of the parasite may occur in patients receiving *CORZOLE 400* treatment for neurocysticercosis (e.g. seizures, raised intracranial pressure, focal signs). These should be treated with appropriate steroid and anticonvulsant therapy. Oral or intravenous corticosteroids are recommended to prevent cerebral hypertensive episodes during the first week of treatment.

Pre-existing neurocysticercosis may also be uncovered in patients treated with *CORZOLE 400* for other conditions, particularly in areas with high taenosis infection. Patients may experience neurological symptoms e.g. seizures, increased intracranial pressure and focal signs as a result of an inflammatory reaction caused by death of the parasite within the brain. Symptoms may occur soon after treatment, appropriate steroid and anticonvulsant therapy should be started immediately.

Excipients

CORZOLE 400 tablets contain sunset yellow FCF which may cause allergic-type reactions.

4.5 Drug Interactions

Cimetidine, praziquantel and dexamethasone have been reported to increase the plasma levels of the albendazole active metabolite responsible for the systemic efficacy of the product.

Ritonavir, phenytoin, carbamazepine and phenobarbital may have the potential to reduce plasma concentrations of the active metabolite of albendazole; albendazole sulfoxide. The clinical relevance of this is unknown, but may result in decreased efficacy, especially in the treatment of systemic helminth infections. Patients should be monitored for efficacy and may require alternative dose regimens or therapies.

4.6 Use in Special Populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.)

- ***Pregnancy***

Albendazole should not be administered during pregnancy or in women thought to be pregnant (see 4.3 *Contraindications*).

- ***Lactation***

Adequate human or animal data on use during lactation are not available.

- ***Elderly***

Experience in patients 65 years of age or older is limited. Reports indicate that no dosage adjustment is required, however, *CORZOLE 400* should be used with caution in elderly patients with evidence of hepatic dysfunction (see *Hepatic Impairment* below and 5.3 *Pharmacokinetic Properties*).

- ***Renal impairment***

Since renal elimination of albendazole and its primary metabolite, albendazole sulfoxide, is negligible, it is unlikely that clearance of these compounds would be altered in these patients. No dosage adjustment is required, however, patients with evidence of renal impairment should be carefully monitored.

- ***Hepatic impairment***

Since albendazole is rapidly metabolised by the liver to the primary pharmacologically active metabolite, albendazole sulfoxide, hepatic impairment would be expected to have significant effects on the pharmacokinetics of albendazole sulfoxide. Patients with abnormal liver function test results (transaminases) prior to commencing albendazole therapy should be carefully monitored.

4.7 Effects on Ability to Drive and Use Machines

There have been no studies to investigate the effect of *CORZOLE 400* on driving

performance or the ability to operate machinery. However, when driving vehicles or operating machinery, it should be taken into account that dizziness has been reported after using *CORZOLE 400* (see 4.8 *Undesirable Effects*).

4.8 Undesirable Effects

Data from large clinical studies were used to determine the frequency of very common to rare undesirable reactions. The frequencies assigned to all other undesirable reactions (i.e. those occurring at $< 1/1000$) were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency.

The following convention has been used for the classification of frequency:

Very common	$\geq 1/10$
Common	$\geq 1/100$ to $< 1/10$
Uncommon	$\geq 1/1000$ to $< 1/100$
Rare	$\geq 1/10,000$ to $< 1/1000$
Very rare	$< 1/10,000$

Use in intestinal infections and Cutaneous Larva Migrans (short duration treatment at lower dose)

Immune system disorders

Rare: Hypersensitivity reactions including rash, pruritus and urticaria

Nervous system disorders

Uncommon: Headache and dizziness

Gastrointestinal disorders

Uncommon: Upper gastrointestinal symptoms (e.g. epigastric or abdominal pain, nausea, vomiting) and diarrhoea.

Hepatobiliary disorders

Rare: Elevations of hepatic enzymes

Skin and subcutaneous tissue disorders

Very rare: Erythema multiforme, Stevens-Johnson syndrome

Use in systemic helminth infections (longer duration of treatment at higher doses)

Blood and the lymphatic system disorders

Uncommon: Leukopenia

Very rare: Pancytopenia, aplastic anaemia, agranulocytosis

Patients with liver disease, including hepatic echinococcosis, appear to be more susceptible to bone marrow suppression (see 4.2 *Posology and Method of Administration* and 4.4 *Special Warnings and Precautions for Use*).

Immune system disorders

Uncommon: Hypersensitivity reactions including rash, pruritus and urticaria

Nervous system disorders

Very common: Headache

Common: Dizziness

Gastrointestinal disorders

Common: Gastrointestinal disturbances (abdominal pain, nausea, vomiting)

Gastrointestinal disturbances have been associated with albendazole when treating patients with echinococcosis.

Hepato-biliary disorders

Very common: Mild to moderate elevations of hepatic enzymes

Uncommon: Hepatitis

Skin and subcutaneous tissue disorders

Common: Reversible alopecia (thinning of hair, and moderate hair loss)

Very rare: Erythema multiforme, Stevens-Johnson syndrome

General disorders and administrative site conditions

Common: Fever

4.9 Overdose

Treatment

Further management should be as clinically indicated.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

ATC code: P02CA03

Mechanism of Action

Albendazole is a benzimidazole carbamate with antiprotozoal and anthelmintic effects against intestinal and tissue parasites. Albendazole exhibits larvicidal, ovicidal and vermifugal activity, and it is thought to exert its anthelmintic effect by inhibiting tubulin polymerisation. This causes the disruption of the helminth metabolism, including energy depletion, which immobilises and then kills the susceptible helminth

Intestinal Infections and Cutaneous Larva Migrans

Albendazole is active against intestinal parasites, including:

- **Nematodes**
Ascaris lumbricoides (roundworm)
Trichuris trichiura (whipworm)
Enterobius vermicularis (pinworm/threadworm)
Ancylostoma duodenale (hookworm)
Necator americanus (hookworm)
Strongyloides stercoralis (threadworm)
 Hookworms that cause cutaneous larva migrans.
- **Cestodes**
Hymenolepis nana (dwarf tapeworm).
Taenia solium (pork tapeworm).
Taenia saginata (beef tapeworm).
- **Trematodes**
Opisthorchis viverrini and *Clonorchis sinensis*.
- **Protozoa**
Giardia lamblia (*intestinalis* or *duodenalis*).

Systemic Helminth Infections

Albendazole is effective in the treatment of tissue parasites, including cystic echinococcosis and alveolar echinococcosis caused by infestation of *Echinococcus granulosus* and *Echinococcus multilocularis*, respectively. Albendazole is also effective in the treatment of neurocysticercosis caused by larval infestation of *Taenia solium*.

Albendazole has been shown (in clinical trials) to eradicate cysts or significantly reduce cyst size in up to 80% of patients with *Echinococcus granulosus* cysts who were treated.

Where cysts have been investigated for viability following treatment with albendazole, 90% have been non-viable in laboratory or animal studies compared to only 10% of untreated cysts.

In the treatment of cysts due to *Echinococcus multilocularis*, a minority of patients were considered to be cured and a majority had an improvement or stabilisation of disease due to albendazole therapy.

5.2 Pharmacokinetic Properties

Absorption

In man, albendazole is poorly absorbed (less than 5%) following oral administration.

The systemic pharmacological effect of albendazole is augmented if the dose is administered with a fatty meal, which enhances the absorption by approximately five-fold.

Distribution

Following oral administration of a single dose of 400 mg albendazole, the pharmacologically active metabolite, albendazole sulfoxide, has been reported to achieve plasma concentrations from 1.6 to 6.0 micromol/L when taken with breakfast.

Metabolism

Albendazole rapidly undergoes extensive first-pass metabolism in the liver, and is generally not detected in plasma. Albendazole sulfoxide is the primary metabolite, which is thought to be the active moiety in effectiveness against systemic tissue infections.

Elimination

The plasma half-life of albendazole sulfoxide is 8.5 hours.

Albendazole sulfoxide and its metabolites appear to be principally eliminated in bile, with only a small proportion appearing in the urine. Elimination from cysts has been shown to occur over several weeks following high and prolonged dosing.

Special Patient Populations

- ***Elderly***

Although no studies have investigated the effect of age on albendazole sulfoxide pharmacokinetics, data in 26 hydatid cyst patients (up to 79 years) suggest pharmacokinetics similar to those in young healthy subjects. The number of elderly patients treated for either hydatid disease or neurocysticercosis is limited, but no problems associated with an older population have been observed.

- ***Renal Impairment***

The pharmacokinetics of albendazole in patients with impaired renal function have not been studied.

- ***Hepatic Impairment***

The pharmacokinetics of albendazole in patients with impaired hepatic function have not been studied.

5.3 Preclinical Safety Data:

Albendazole has been shown to be teratogenic and embryotoxic in rats and rabbits. Albendazole was negative for evidence of mutagenicity or genotoxicity in a panel of *in vitro* (including Ames inactivated and activated) and *in vivo* tests. In long-term toxicity studies conducted in rats and mice at daily doses of up to 30 times the recommended human doses, no

treatment-related tumour formation was seen.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients:

Microcrystalline Cellulose

Maize Starch

Sunset Yellow FCF

Povidone K 30

Macrogol 4000

Purified Water

Colloidal Anhydrous Silica

Purified Talc

Magnesium Stearate

Aspartame

Xanthan Gum

Flavour Dry Orange

6.2 Incompatibilities

No incompatibilities have been identified.

6.3 Shelf Life

36 Months from the date of manufacture

6.4 Packaging Information

Store below 30°C in a dry place. Protect from light.

Keep Medicine out of reach of children.

6.5 Nature and Contents of Container:

Primary Packing: Alu-PVC blister of 7 Tablets.

Secondary Packing: Such 10 blisters are packed in a carton along with Pack insert.

6.6 Special precautions for disposal:

Any unused product or waste material should be disposed of in accordance with local regulatory requirements.

7. MARKETING AUTHORIZATION HOLDER
CORAL LABORATORIES LTD.

Plot No.57 / 1 (16),
Bhenslore, Dunetha,
Nani Daman - 396 210.
INDIA.

8. MARKETING AUTHORIZATION NUMBER
COR/IND/009

9. DATE OF FIRST AUTHORIZATION / RENEWAL OF AUTHORIZATION:

FIRST AUTHORIZATION: 05-08-2014

10. DATE OF REVISION OF THE TEXT

14/7/2023

11 REFERENCES